Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Global Blood Therapeutics (GBT) Surges: Stock Moves 6.9% Higher

Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT Stock Investors to Know as Shares Tumble appeared first on InvestorPlace.

Global Blood Therapeutics News: 5 Things for GBT Stock Investors to Know as Shares Tumble

Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.

Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript

Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics (GBT) Reports Q3 Loss, Lags Revenue Estimates

Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020

GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results

Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting  Long-Term Use of Oxbryta ® ( voxelotor )

GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after U.S. financial markets close.

GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020

﻿Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation

GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia

Iovance Biotherapeutics

Reata Pharmaceuticals

Smaller biotechs would make nice additions to pharma companies in similar areas of therapy

Global Blood, Iovance and Reata Make Takeover List

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award ® for Industry Innovation from the National Organization for Rare Disorders (NORD). GBT received the award for Oxbryta® (voxelotor) tablets at a virtual event on October 9, 2020, following NORD’s annual Rare Disease and Orphan Products Breakthrough Summit.

GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets

Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D.

GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference

More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates

GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Why Is Global Blood (GBT) Down 5.6% Since Last Earnings Report?

Global Blood Therapeutics (NASDAQ: GBT) shares are trading higher on Tuesday after Raymond James initiated coverage on the company's stock with an Outperform rating and announced a $115 price target.

Why Global Blood Therapeutics Is Trading Higher Today

Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2020 Results - Earnings Call Transcript

Achieved Oxbryta® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions     

GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results

Camping World Hlds

Fiserv

Fastly

Medifast

ResMed

Cimarex Energy

Seven top-ranked companies are poised to beat on earnings today after the closing bell.

Top 7 Stocks Set to Beat on Earnings Today After Market

SOUTH SAN FRANCISCO, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, after U.S. financial markets close.

GBT to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020

Mesoblast

Ovid Therapeutics

Here are the best biotech stocks for investors looking for market-beating performance.

3 Top Biotech Stocks to Buy Now

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs.

Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns

SOUTH SAN FRANCISCO, Calif., June  25, 2020  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell disease (SCD) community have been awarded a total of $250,000 through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. For the second year, the ACCEL program has funded innovative programs that have the potential to deliver high-quality healthcare to people living with SCD.

GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

Global Blood to Seek Approval of Oxbryta in Europe for SCD

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease

News for Global Blood Therapeutics Stock (GBT)